Last reviewed · How we verify
Topical IOP-lowering drugs
Topical IOP-lowering drugs work by reducing intraocular pressure through the reduction of aqueous humor production or increase in aqueous humor outflow.
Topical IOP-lowering drugs work by reducing intraocular pressure through the reduction of aqueous humor production or increase in aqueous humor outflow. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Topical IOP-lowering drugs |
|---|---|
| Sponsor | Bayer |
| Drug class | Topical IOP-lowering agents |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Topical IOP-lowering drugs, such as prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors, act on the ciliary body to decrease aqueous humor production or increase outflow, thereby reducing intraocular pressure. This mechanism is crucial in managing conditions like glaucoma and ocular hypertension.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Eye irritation
- Headache
- Eye redness
Key clinical trials
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- Effect of Citicoline/Homotaurine on PERG in Primary Open Angle Glaucoma (NA)
- A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- MINIject Glaucoma Implant in European Patients (NA)
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 (PHASE2)
- A Trial of China Laser and Surgery Study Glaucoma in Rural China (EARLY_PHASE1)
- Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections (NA)
- Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical IOP-lowering drugs CI brief — competitive landscape report
- Topical IOP-lowering drugs updates RSS · CI watch RSS
- Bayer portfolio CI